Hirayama Disease: A Comprehensive Clinical Review
Introduction
Hirayama disease (HD), also known as monomelic amyotrophy (MMA), juvenile non-progressive amyotrophy, Sobue disease, or benign monomelic amyotrophy, is a rare benign motor neuron disorder characterized by insidious onset of progressive weakness and atrophy of the distal upper limb musculature in young males, followed by spontaneous cessation of progression within 2–5 years. First described by Hirayama and colleagues in 1959 in Japan, this condition represents a distinctive form of lower motor neuron disease with a pathophysiology involving dynamic cervical spinal cord compression during neck flexion.[1][2][3][4][5][6][7][8]
Although historically more frequently recognized in Asian populations—particularly Japan and India—Hirayama disease has a worldwide distribution and should be considered in the differential diagnosis of any young male presenting with progressive distal upper limb weakness and atrophy. The recognition of its benign, self-limiting nature and characteristic imaging findings has become increasingly important for appropriate diagnosis and management.[4][6][7][9][10][8][1]
History and Epidemiology
Historical Background
Hirayama disease was first described in 1959 by Hirayama and colleagues who reported a series of cases with what they termed “juvenile non-progressive muscular atrophy of the distal upper extremity,” distinct from classic motor neuron disease with progressive deterioration. The subsequent recognition that this was not a familial condition and that it typically halted progression after a limited time period led to classification as a distinct benign entity.[6][7][11]
Epidemiology
Prevalence and Incidence
- Hirayama disease is extremely rare, with an estimated incidence of approximately 1–10 cases per 10 million individuals per year[7][8][6]
- Accounts for 0.1–1.3% of motor neuron diseases depending on geographic location and population studied[2][12][4]
Geographic Distribution
- Most common in Asia:
- True prevalence may be underestimated due to diagnostic challenges and potential underrecognition, particularly in non-endemic regions[6][7]
Demographic Characteristics
Age and Gender:
- Predominantly affects young males – approximately 94–100% of reported cases are male[14][2][4][12][7][8]
- Age at onset: Mean age 18–22 years, typically during late adolescence or early adulthood[9][10][1][2][4][7]
- Range: Usually between 15–25 years of age, with rare cases presenting in the late 30s (late-onset presentations)[3][15]
- Peak incidence: In the second decade of life, often coinciding with or shortly after the major adolescent growth spurt[4][7][8][6]
No Genetic Predisposition:
- Hirayama disease is not hereditary – familial occurrence is exceptionally rare[7][8][4]
- No known genetic mutations have been identified as causative[12][8]
Pathophysiology
Mechanical Compression Theory (Most Widely Accepted)
The leading hypothesis for the pathogenesis of Hirayama disease involves repeated or sustained neck flexion causing forward displacement and compression of the cervical spinal cord.[16][1][9][8][4][6][7]
Proposed Mechanism
Static and Dynamic Factors:
- During neck flexion, the posterior wall of the cervical dural sac moves anteriorly due to loss of attachment between the posterior dura and subjacent lamina[9][16][6]
- This forward displacement is markedly amplified during neck flexion (approximately 30–40° flexion)[14][16][9]
- The lower cervical cord (C5–T1) becomes compressed against the anterior cervical structures, leading to flattening and distortion of the cord[2][16][8][4][9]
- In some patients, the cervical spine shows loss of normal lordosis (straight or kyphotic curvature), predisposing to greater anterior dural shift[16][2][17]
Microcirculatory Changes
Ischemic Hypothesis:
- Chronic compression leads to chronic microcirculatory disturbances in the territory of the anterior spinal artery[8][2][4][9][18]
- The anterior horn cells of the lower cervical cord are particularly vulnerable to ischemia and are affected first[4][7][9][16]
- Repeated or sustained neck flexion perpetuates ischemic injury, leading to progressive necrosis of anterior horn cells[7][9][16][8][4]
- This explains why the disease predominantly affects the C7, C8, and T1 myotomes (intrinsic hand muscles, ulnar forearm muscles)[3][9][8][11]
Relationship to Adolescent Growth
- The timing of symptom onset during or shortly after the adolescent growth spurt suggests that rapid longitudinal growth of the body outpaces growth of the spinal cord and dural sac[1][6][8][4][7]
- This creates a relative mismatch between spinal cord length and dural sac length, predisposing to compression during flexion[8][4]
- This hypothesis explains why the disease typically manifests in young males, who undergo more pronounced growth during adolescence[4][7]
Alternative and Complementary Pathogenic Factors
While mechanical compression is the predominant theory, emerging research suggests additional factors may contribute:[6][9]
Immunological Factors:
- Some evidence suggests immune-mediated anterior horn cell damage may play a complementary role[6]
- Cytokine abnormalities and inflammatory markers have been reported in some patients[13]
Musculoskeletal and Postural Factors:
- Habitually poor posture or repetitive neck flexion (occupational or habitual) may exacerbate cord compression[7][4][6]
- The observation of improvement with postural modification and cervical collar use supports this hypothesis[12][6]
Vascular and Metabolic Changes:
- Abnormal posterior epidural venous drainage with congestion of the posterior internal vertebral venous plexus has been noted on dynamic MRI[19][9][16]
- This may contribute to reduced parenchymal blood flow and ischemia[9][16]
Clinical Features
Clinical Presentation
Hirayama disease presents with a distinctive clinical pattern that, when recognized, enables diagnosis:[2][9][4][7][6]
Characteristic Features (Diagnostic Criteria)
- Insidious Onset of Progressive Weakness and Atrophy
- Distal Upper Limb Predilection
- Muscles particularly affected:
- Intrinsic hand muscles (interossei, lumbricals)
- Muscles particularly affected:
- Unilateral or Asymmetrically Bilateral Presentation
- Preserved Sensation and Reflexes
- Non-Progressive Course
Associated Symptoms
Commonly Reported:
- Cold paresis: Marked worsening of weakness in cold environments – reported in 30–50% of patients[14][3][7][9][4]
- Fasciculations: Visible muscle twitching, reported in 20–40% of patients[8][3][9][4]
- Tremor: Postural or action tremor in some patients[3][7][8]
- Muscle cramps: Intermittent cramping, particularly in affected forearm[7][8][3]
- Pain: Not a primary feature; sharp pains in neck or radiating to hand are unusual and warrant consideration of other diagnoses[8]
Rarely Reported:
- Fatigue: Muscular fatigue reported in some cases[3][4]
- Paresthesias: Uncommon; suggests alternative diagnosis if present[4][4]
Atypical Presentations
Atypical or late-presenting cases of Hirayama disease have been increasingly recognized:[20][13][6][3][4]
- Late presentation beyond age 30 years[15][3]
- Bilateral symmetric amyotrophy rather than asymmetric pattern[7][3]
- Extension beyond C7–T1 myotomes – for example, affecting forearm extensors or proximal muscles[14][3]
- Associated sensory changes (usually indicates alternative diagnosis)[20][6]
- “Snake eye sign” on cross-sectional MRI (symmetric bilateral anterior horn cell involvement with rim-like preservation)[15][14][3]
Diagnostic Approach
Clinical Diagnosis Criteria
A diagnosis of probable Hirayama disease can be made clinically based on the following established criteria:[9][2][8][4]
- Male gender (strongly suggestive, though not absolute)
- Age of onset 15–25 years (typically adolescence to early adulthood)
- Insidious onset of progressive distal upper limb weakness and atrophy
- C7–C8–T1 myotome distribution
- Unilateral or asymmetrically bilateral presentation
- Absence of sensory loss
- Intact deep tendon reflexes
- Spontaneous cessation of progression within 2–5 years
- Absence of other clinical features suggestive of alternative motor neuron disease (pyramidal signs, lower limb involvement, sphincter dysfunction)
- Evidence of chronic denervation on electromyography
Electromyography and Nerve Conduction Studies
Electromyography (EMG):
- Demonstrates neurogenic changes consistent with chronic denervation in affected muscles[5][2][9][8][4]
- Fibrillations and positive sharp waves in 30–50% of patients[2][9]
- Fasciculations in 30–40% of patients[9][2][4]
- Increased motor unit action potential duration and amplitude (reflecting chronic reinnervation)[2][4]
- Changes localized to C7, C8, T1 myotomes[4][9][2]
- Brachioradialis often relatively spared, aiding diagnosis[8][9][2]
Nerve Conduction Studies:
- Motor nerve conduction velocities: Normal or near-normal[9][8][2][4]
- Compound muscle action potentials (CMAPs): Reduced in affected muscles due to loss of motor units[2][9]
- Sensory nerve action potentials (SNAPs): Normal or near-normal[8][4][9][2]
- Absence of conduction block – important distinguishing feature from demyelinating neuropathies[7][20]
Interpretation:
The combination of normal conduction velocities with reduced amplitudes and chronic denervation patterns is highly suggestive of lower motor neuron disease with anterior horn cell involvement, consistent with Hirayama disease.[4][9][8]
Magnetic Resonance Imaging (MRI) – Gold Standard
MRI is the most important confirmatory diagnostic test.[21][10][14][6][9][8][2][4]
Neutral Position MRI Findings
Abnormal Cervical Curvature:
- Loss of normal cervical lordosis – present in 27–45% of patients[9][2]
- Straight cervical spine or kyphotic curvature predisposes to greater anterior dural displacement during flexion[2][4][9]
Cervical Cord Atrophy:
- Localized lower cervical cord atrophy (C4–C7 level, especially C5–C6) – present in 72% of patients[9][2]
- Cord diameter typically 4–6 mm (normal is 10–12 mm)[14][4]
- Atrophy may extend into dorsal cord (61% of cases)[2]
Cord Flattening:
- Asymmetric flattening of the cervical cord, often appearing pear-shaped on axial images[9][20]
- Asymmetry correlates with side of clinical involvement[4][2][9]
Intramedullary Signal Changes:
- T2 hyperintensity in cord parenchyma in 39–45% of patients[2][9]
- Represents gliosis or demyelination[4][9][2]
- May indicate more significant cord damage[14]
Loss of Attachment:
- Detachment of the posterior dural sac from the subjacent spinal laminae – present in 100% of patients[19][9][2]
- Best appreciated on sagittal images[9][20]
- Represents key pathognomonic finding[16][19][9]
Flexion Position MRI Findings
Dynamic Anterior Displacement of Dura:
- Forward displacement of the posterior wall of the cervical dural sac during neck flexion – hallmark finding[19][16][14][4][2][17]
- Maximal displacement typically at C5–C6 and C6–C7 levels[16][2][9]
- Dural sac shows marked narrowing during flexion[16][2][9]
Cord Compression:
- Significant anterior flattening and narrowing of the cervical cord during flexion[16][14][4][2][9]
- Cord diameter may decrease by 30–50% with flexion[14][16][9]
Posterior Epidural Space Abnormalities:
- Crescent-shaped or crescentic epidural mass in the posterior epidural space during flexion[19][16][4][2][9]
- Composed of congested posterior internal vertebral venous plexus rather than neoplasm or vascular malformation[19][16][9]
- Flow voids visible, indicating vascular nature[19][2][9]
- Vanishes on return to neutral position, a characteristic feature[16][2][9]
Advanced MRI Sequences
3D-FIESTA and 3D-CISS:
- 3D-FIESTA (3D Fast Imaging Employed Steady-State Acquisition) and 3D-CISS (Constructive Interference Steady State) sequences provide superior visualization of cord morphology and dural displacement[19][14][2][17]
- Excellent CSF-to-tissue contrast enabling detailed assessment of compression and cord changes[19][2]
- Better visualization of “snake eye sign” (symmetric anterior horn involvement) in some patients[15][14][3]
Diagnostic Accuracy of MRI
Recent meta-analyses indicate:82–100% sensitivity and 85–95% specificity for diagnosing Hirayama disease when flexion MRI is performed.[10][6][8][4][2][9]
Key diagnostic findings on neutral position MRI alone:
- Abnormal cervical curvature, localized lower cervical cord atrophy, asymmetric cord flattening, loss of attachment between posterior dural sac and lamina, and intramedullary T2 signal abnormalities collectively have ~80% accuracy[22][9]
- Loss of attachment is the single most valuable finding for diagnosis in neutral position[22][9]
Other Diagnostic Studies
Imaging:
- Cervical spine X-rays: Usually show no specific abnormalities; may reveal straight or kyphotic cervical curvature[16][7][4]
- CT myelography: Shows forward movement of posterior dural wall during flexion; used historically before MRI availability[16][7]
- Ultrasound: Not routinely useful for diagnosis[4]
Laboratory:
- Cerebrospinal fluid: Normal (if lumbar puncture performed)[7][4]
- Serum biomarkers: No specific markers; phosphorylated tau or neurofilament testing might show elevations consistent with neurodegeneration, but not specific to HD[6]
Differential Diagnosis
Accurate diagnosis is crucial because Hirayama disease is benign and self-limiting, whereas alternative diagnoses may require aggressive treatment:[1][5][6][7][2]
| Condition | Key Distinguishing Features |
| Amyotrophic lateral sclerosis (ALS) | Upper motor neuron signs, progressive course without arrest, younger age not typical, abnormal speech/swallowing[4][5][7] |
| Cervical myelopathy (degenerative) | Older age, cervical spondylosis on imaging, pyramidal signs, gait disturbance[20][7] |
| Cervical spinal cord tumor | Fixed, progressive course, pain, sensory level, abnormal mass on MRI that does not change with position[2][7] |
| Cervical spondylosis with myelopathy | Older age, degenerative disc disease, pyramidal signs, gait dysfunction[2][4][7] |
| Syringomyelia | Presence of intramedullary syrinx on MRI, sensory level, pain, progressive course[20][4] |
| Thoracic outlet syndrome | Vascular compression, sensory symptoms, abnormal vascular studies, different distribution[4][7] |
| Ulnar neuropathy | Electrodiagnostic evidence of conduction block at elbow, normal EMG elsewhere[2][4] |
| Brachial plexopathy | Acute or subacute onset, associated trauma/Parsonage-Turner, widespread proximal involvement[2][11] |
| Peripheral neuropathy | Distal, symmetric, bilateral involvement; sensory loss; normal EMG localization[2][11] |
| Spinal muscular atrophy (SMA) | Acute/infantile onset; younger age; proximal involvement; genetic testing positive[4][7] |
| Poliomyelitis | Acute febrile illness; epidemic history; worldwide elimination with vaccination[2][4] |
| Infantile X-linked spinal muscular atrophy | Early childhood onset; proximal predominance; different genetic basis[4] |
Management
There is no cure for Hirayama disease. Management is conservative and symptomatic, focused on preventing progression, halting disease evolution, and optimizing functional outcomes.[21][10][1][5][6][2][9]
Conservative Management (First-Line)
Cervical Collar (Cervical Orthosis)
Indications and Rationale:
- Primary therapeutic intervention for most patients with HD[21][10][1][5][6][2][9]
- Objective: prevent or limit neck flexion, reducing dynamic spinal cord compression[6][16][2][9]
- Should be implemented as soon as diagnosis is confirmed[10][5][2]
Duration and Use:
- Recommended for 3–5 years in most cases[10][5][6][2]
- Should be worn consistently, particularly during activities and occupational tasks that involve neck flexion[5][2][9]
- Can be discontinued once neurological stabilization is confirmed through clinical and electrophysiological assessment[10][5][2]
Effectiveness:
- Most patients show cessation or significant slowing of progression with cervical collar use[1][5][10][2][9]
- Clinical improvement has been documented in some patients who scrupulously avoid prolonged neck flexion[12][5]
- Compliance and consistent use are critical determinants of treatment success[10][6][2][17]
Postural Modification and Activity Counseling
- Avoid sustained or repetitive neck flexion, particularly occupational neck flexion (desk work, prolonged computer use)[6][7][2][9]
- Maintain neutral or extended neck posture during daily activities[5][2][17]
- Ergonomic modifications at work to minimize flexion demands[2][9]
- Education on cold exposure: Cold paresis may be managed through avoidance of cold environments when possible; keep affected limb warm[3][4][9]
Rehabilitation and Physical Therapy
- Range of motion exercises: Gentle, non-forceful mobility exercises to maintain upper limb function[5][9][2]
- Strengthening exercises: Progressive resistance exercises targeting spared proximal muscles and unaffected limb[5][9][2]
- Functional training: Occupational therapy to optimize use of unaffected hand and develop adaptive strategies[5][9][2]
- Activity modification: Training in compensation strategies[5][17]
Pharmacological Treatment
Limited evidence for medication efficacy:
- No pharmacological agent has demonstrated clear benefit for HD[6][9][2]
- Drugs targeting ALS (riluzole, edaravone) have not been studied specifically in HD[6][9]
- Supportive medications may be used for symptom management (e.g., pain relief if paresthesias present)[17]
Surgical Management
Indications:
Surgical intervention is considered for patients with:****[12][21][23][14][6][17]
- Continued progression despite conservative management for >3–5 years[24][21]
- Severe functional impairment limiting activities of daily living[24][21]
- Young age at presentation, giving longer disease duration[24][21]
- Patient preference and counseling regarding benefits and risks[21][24]
Surgical Approaches:
- Cervical Decompression with or without Fusion:
- Anterior cervical decompression and fusion (ACDF) or posterior cervical fusion at affected levels[24][21]
- Prevents forward dural displacement during flexion[21]
- Posterior Fixation and Fusion:
- Posterior cervical fusion with lateral mass screw instrumentation at C4–C6 or C4–C7[21]
- Results in stabilization and prevents dural sac movement during flexion[21]
- Case reports document improvement in muscle strength and reversal of muscle wasting at 12-month follow-up[21]
- Cervical Duraplasty:
- Dural sac enlargement through duraplasty (opening dural sac and patching) combined with decompression[23]
- Increases cerebrospinal fluid space around compressed cord[23]
- Results in significantly altered clinical course with arrested forward cord migration during flexion[23]
- Promotes morphological recovery of the cord[23]
- 85% of patients undergoing duraplasty demonstrate clinical and electrophysiological improvement at mid-term follow-up[23]
Surgical Outcomes:
- Meta-analysis shows ~85% improvement in neurological symptoms regardless of surgical approach[25]
- Higher improvement rates in patients younger than 20 years[8]
- Long-term follow-up studies are limited; further research needed to determine durability of benefit[25][10]
Controversies:
- Surgical management remains controversial due to benign, self-limiting nature of disease[24][21][6][9]
- Most patients stabilize with conservative treatment within 2–3 years, questioning need for surgery[24]
- Surgical complications (infection, fusion-related morbidity) must be weighed against potential benefits[24][21]
- Individualized decision-making recommended[10][21][6][9]
Monitoring and Follow-Up
Clinical Assessment:
- Regular neurological examinations every 3–6 months during active disease phase[10][5][6][2]
- Assessment of strength, atrophy progression, and functional status[5][2][9]
- Documentation of cold paresis and other symptom fluctuations[9]
Electrophysiological Monitoring:
- EMG and NCS at baseline and periodically during disease course to document progression and stabilization[10][5][2][9]
- Motor-evoked potentials (MEPs) may guide timing of cessation of cervical collar use[10][5][2]
- Stabilization of motor unit recruitment patterns and reduced fibrillation activity suggest disease plateau[5][2]
Imaging Monitoring:
- Repeat cervical MRI may be obtained to document cessation of cord changes or improvement in cord atrophy after conservative or surgical treatment[10][5][2][9]
- Flexion MRI can assess adequacy of treatment in preventing dural sac displacement[23][5][2]
Prognosis and Natural History
Disease Progression
Characteristic Pattern:
- Progressive phase: 2–5 years of gradual symptom worsening[1][8][7][10][5][4][2]
- Plateau phase: Spontaneous cessation of progression, typically by age 25–30 years[1][8][7][5][4][20]
- Progression does not typically continue beyond 5 years[7][4][20]
Functional Outcome
Variable but Generally Favorable:
- Hand/forearm function: Residual weakness and atrophy persist, but degree of residual dysfunction is variable[8][5][2][9]
- Proximal arm function: Generally preserved[7][5][4][2]
- Lower extremities: Unaffected, preserving ambulation and mobility[7][4][2]
- Sensory function: Preserved[4][7][2]
- Cognitive function: Preserved[7][2]
Mortality
- No shortened life expectancy – Hirayama disease is a benign, non-fatal condition[8][5][2][7]
- Death is not caused by the disease itself[5][2][7]
Comparison to Other Motor Neuron Diseases
Hirayama disease differs fundamentally from progressive motor neuron diseases like ALS:
- ALS: Progressive deterioration, multiple system involvement, fatal within 2–5 years[2][7]
- Hirayama disease: Limited single-region involvement, self-limiting progression, preserved lifespan[7][2]
Prognostic Factors
Favorable Prognostic Indicators:[10][5][2]
- Younger age at onset[14][6][10][9]
- Short disease duration at diagnosis[10][2]
- Mild or absent cervical cord atrophy on initial imaging[10][2]
- Prompt initiation of conservative management[6][5][10][2]
- Good compliance with cervical collar use[5][2][9]
Less Favorable Prognostic Indicators:[6][10][2]
- Older age at presentation[14][10]
- Long disease duration before diagnosis[6][2]
- Severe cervical cord atrophy on initial imaging[10][2][9]
- Bilateral symmetric involvement[3][14][2]
- Continued progression despite conservative management[5][2]
Quality of Life
- Most patients maintain functional independence in activities of daily living[2][5][9][10]
- Occupational impact: May require job modification or change if prior role involved significant upper limb use[5][2]
- Psychological impact: Diagnosis of benign, non-progressive disease is generally reassuring after concerns about ALS[2][3]
- Cosmetic concerns: Visible hand atrophy may cause some social or self-esteem issues in a minority of patients[5][2]
Key Clinical Pearls
- High suspicion in young Asian males with distal unilateral upper limb weakness should prompt consideration of Hirayama disease[1][7][2]
- Absence of sensory loss is a key distinguishing feature – sensory involvement suggests alternative diagnosis[4][7][2]
- Brachioradialis sparing on EMG is a helpful diagnostic clue for Hirayama disease[8][9][2]
- Flexion MRI is essential for diagnostic confirmation – neutral position alone may miss disease[14][4][9][10][2]
- Benign prognosis – emphasizing self-limiting nature and spontaneous arrest is reassuring for patients who may fear ALS[7][2][5]
- Conservative management (cervical collar + activity modification) is effective in most cases and should be first-line treatment[1][21][6][9][10][2][3]
- Surgical intervention should be reserved for refractory cases with persistent progression despite conservative measures[24][21][6][9]
Conclusion
Hirayama disease is a rare benign motor neuron disorder presenting as progressive distal upper limb weakness and atrophy in young males, characterized by spontaneous cessation of progression within 2–5 years. The pathophysiology involves dynamic cervical spinal cord compression during neck flexion, resulting from a mismatch between spinal cord length and dural sac length, particularly in the context of adolescent growth.
Diagnosis is established through clinical evaluation combined with characteristic MRI findings (cord atrophy, loss of dural attachment, dynamic anterior dural displacement during flexion) and electrophysiological evidence of chronic denervation. The benign, self-limiting natural history distinguishes Hirayama disease from progressive motor neuron diseases like ALS, a crucial distinction for appropriate management and counseling.
Conservative management with cervical collar and postural modification is first-line therapy and effective in most patients. Surgical intervention is reserved for patients with refractory progression despite conservative measures. With appropriate diagnosis, counseling, and management, affected individuals can achieve good functional outcomes and normal life expectancy.[1][21][8][6][4][9][10][7][2]
References
- Karger – Monomelic Amyotrophy (Hirayama Disease)[1][5]
- Russian Medical Inquiry – Atypical Hirayama Disease Case Report[20]
- Sage Medical Journal – Clinical Profile and Dynamic MRI in Hirayama Disease: Nepal Study[14][2]
- Journal of Medical and Scientific Research – Monomelic Amyotrophy Case Report[12]
- Cureus – Late Presentation of Hirayama Disease with “Snake Eye Sign”[15][3]
- Journal of Diagnostic Radiology – Significance of Dynamic Imaging in Diagnosis[22][4]
- Kansas Journal of Medicine – Significance of Dynamic Imaging[4]
- PubMed Central – Clinical Improvement after Avoidance of Neck Flexion[12]
- Journal of Neurosurgery – Cervical Duraplasty Outcomes[23]
- Journal of Clinical Orthopedics and Trauma – Hirayama Disease Case Report[26]
- Update on Pathogenesis, Clinical Diagnosis, Treatment[6]
- Wikipedia – Hirayama Disease[8][7]
- PubMed Central – MRI Findings in Hirayama Disease[9]
- Journal of Orthopaedic Case Reports – Hirayama Disease Case Report[16]
- Rural Neuropractice – Imaging in Hirayama Disease[19]
- PubMed Central – Hirayama Disease Successfully Treated by Posterior Fixation[21]
- PubMed Central – Case Report and Review of Literature[10]
- Neurologia – Hirayama Disease: Is Surgery an Option?[24]
- Neurosurgery Forum – Surgical Management of Hirayama Disease[25]
Sources
- https://karger.com/article/doi/10.1159/000508994
- https://journals.lww.com/10.1097/MS9.0000000000000664
- https://www.cureus.com/articles/73066-late-presentation-of-hirayama-disease-with-snake-eye-sign-a-case-report
- https://journals.ku.edu/kjm/article/view/13530
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7549014/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8844368/
- https://en.wikipedia.org/wiki/Monomelic_amyotrophy
- https://en.wikipedia.org/wiki/Hirayama_disease
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3056618/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11417289/
- http://jmscr.igmpublication.org/v11-i4/17 jmscr.pdf
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4435551/
- https://www.semanticscholar.org/paper/991bde9aeec93b95312f0ef9f876b6f891a77fe3
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11418759/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8865601/
- https://jocr.co.in/wp/2013/07/2250-0685-107-fulltext/
- https://www.jemds.com/data_pdf/1_Murugan(shaik sulaiman).pdf
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11715077/
- https://ruralneuropractice.com/imaging-in-hirayama-disease/
- https://www.rusmedreview.com/articles/nevrologiya/Atipichnaya_forma_bolezni_Hirayama_klinicheskoe_nablyudenie/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11152793/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7100947/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC8559061/
- https://www.elsevier.es/en-revista-neurologia-english-edition–495-articulo-hirayama-disease-is-surgery-an-S2173580815001145
- https://www.sciencedirect.com/science/article/abs/pii/S187887502300013X
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4719247/
- https://www.semanticscholar.org/paper/4e546238fc4d5b4a4d2d3b4d313f853eb5b1a02d
- https://www.semanticscholar.org/paper/35f7b532e865ea0d0237621ac2b45e604917b83f
